About me
Craig Thompson, CEO of Cerevance, brings over 25 years of commercial and marketing leadership experience in the biotech and pharmaceutical industries. Prior to joining Cerevance, he was the president and CEO of Neurana Pharmaceuticals, a private company focused on the treatment of neuromuscular conditions.
Before his role at Neurana, Craig served as president and CEO of Anthera Pharmaceuticals, where he led the company’s efforts in developing treatments for autoimmune diseases and cystic fibrosis. Prior to Anthera, Craig was the chief operating officer of Tetraphase Pharmaceuticals. In this capacity, he managed the development and implementation of marketing, market access, reimbursement, and sales strategies.
Earlier in his career, Craig served as chief commercial officer for Trius Therapeutics. At Trius, he played a crucial role in the company's acquisition by Cubist Pharmaceuticals for more than $700 million as well as the partnership with Bayer for commercialization rights for the company’s lead program in Asia Pacific and other territories.
Craig held various operational and commercial roles of increasing responsibility at Pfizer and Merck, with roles as VP of Marketing for Specialty Care as well as Group Leader for Allergy, Respiratory, Pulmonary Vascular Disease and Immunology. During his time at these companies, he gained extensive experience in clinical development, product management, and market development, and contributed to the successful commercialization of multiple blockbuster drugs. His comprehensive background in both large pharmaceutical and smaller biotech companies has equipped him with a broad perspective and a versatile skill set, making him a seasoned leader in the industry.